Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2016/V13/I6/380

[1] 郑晓兰.卡托普利致血管神经性水肿1例[J].山东医药，2010,50（15）：3.
[2] 徐航，张海霞，周庆.卡托普利致血管神经性水肿1例[J].中国药师，2009, 12（8）:1138.
[3] 刘燕红，徐莹钧.卡托普利致血管神经性水肿1例[J].现代中西医结合杂志，2007, 16（32）:4839.
[4] 钟松阳,毛晓华,周美娟.药源性血管神经性水肿122例分析[J].海峡药学, 2007, 19(2):97-98.
[5] 陈岩.应用卡托普利后发生声带、会厌水肿致呼吸心搏骤停1例[J].沈阳部队医药，2008,21（5):319
[6] 王金英，松贞.依那普利引起血管神经性水肿致窒息1例[J].中国药物警戒，2008,5 （1）：53.
[7] 刘依凌.依那普利致血管神经性水肿1例[J].实用医药杂志，2014, 31（4）：329.
[8] 王锋，汪年松，薛勤，等.洛汀新引起面部血管神经性水肿1例报道及文献复习[J].中国基层医药，2005, 12（2）：241.
[9] 税开森，郑永咏，姜明云，等.贝那普利致严重过敏反应[J].药物不良反应杂志，2002，4（5）：343.
[10] 覃乃芳，王毅，杜敬东，等.福辛普利钠致全身血管神经性水肿1例[J].中国临床药学杂志，2002, 11（2）：111.
[11] Vleeming W,Van Amsterdam J G,Stricker B H,er al. ACE inhibitorinduced angioedema.Incidence,prevention and management[J].Drug Saf,1998, 18(3):171-188.
[12] Cicardi M, Zingale L C,Bergamaschini L, et at.Angioedema associated with angiotensin-converting enzyme inhibitor use:outcome after switching to a differernt treatment[J].Arch InternMed,2004,164(8):910-913.
[13] Hernandez-Hernandez R,Soas-Canache B,Belasco M,et al.Angiotensin Ⅱreceptou antagonists role in arterial hypertension[J].JHum Hypertens, 2002, 16(Suppl 1):S93-S99.
[14] Grossman E,Messerli F H,Neutel J M. AngiotensinⅡ receptor blockers:equal or preferred substitutes for ACE inhibitors? [J].Arch Intern Med, 2000, 160:1905-1911.
[15] Haymore B R,Yoon J,Mikita C P,et al.Risk of angioedemawith angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors:a meta-analysis[J].Annals of Allergy Asthma & Immunology,2008, 101(5):495-499.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.